ERBB3 and cancer: The results described above led us to postulate that suppressing the RAS-RAF-MAPK pathway at multiple levels in combination with anti-ErbB3 mAbs is able to control and reduce cancer growth for a longer time by inhibiting the early and the long-term adaptive mechanisms centered around ErbB3.